- Home
- IMNM vs SLNO Comparison
IMNM vs SLNO Comparison
Compare IMNM & SLNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMNM | SLNO |
|---|---|---|
| Founded | 2006 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.3B |
| IPO Year | 2020 | 2014 |
Fundamental Metrics
Financial Performance| Metric | IMNM | SLNO |
|---|---|---|
| Price | $19.62 | $30.24 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 11 |
| Target Price | $32.80 | ★ $105.27 |
| AVG Volume (30 Days) | 1.1M | ★ 1.5M |
| Earning Date | 03-03-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 51.40 | ★ 108.90 |
| EPS | N/A | ★ 0.39 |
| Revenue | ★ $6,941,000.00 | $1,450,788.00 |
| Revenue This Year | N/A | $150.65 |
| Revenue Next Year | $1,127.34 | $56.10 |
| P/E Ratio | ★ N/A | $81.72 |
| Revenue Growth | N/A | ★ 138.82 |
| 52 Week Low | $5.15 | $30.11 |
| 52 Week High | $27.65 | $89.12 |
Technical Indicators
Market Signals| Indicator | IMNM | SLNO |
|---|---|---|
| Relative Strength Index (RSI) | 37.99 | 28.38 |
| Support Level | $19.26 | N/A |
| Resistance Level | $22.57 | $41.48 |
| Average True Range (ATR) | 1.03 | 1.85 |
| MACD | -0.03 | -0.34 |
| Stochastic Oscillator | 1.14 | 7.54 |
Price Performance
Historical ComparisonAbout IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.
About SLNO Soleno Therapeutics Inc.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.